Patent Application
20110137245
The present application relates to medical catheters and more specifically to balloon catheters useful for therapeutic treatment within a body vessel and/or useful for dilation of narrowed portions within a body vessel.
Although many medical conditions are satisfactorily treated by the general systemic administration of a therapeutic agent, the treatment of a many conditions require delivery of the therapeutic agent locally within a body vessel to a selected portion of internal body tissue, without delivery of the therapeutic agent to surrounding tissue or requiring systemic delivery of the therapeutic agent. A systemically administered therapeutic agent may be absorbed not only by the tissues at the target site, but also by other areas of the body. As such, one drawback associated with the systemic administration of therapeutic agents is that areas of the body not needing treatment are also affected.
Medical delivery catheters provide a minimally invasive means for delivering therapeutic agents to internal body tissue. To provide site-specific localized treatment, balloon catheters may be used to deliver a therapeutic agent exclusively to the target site within a body vessel. One example of a condition that is beneficially treated by local administration of a therapeutic agent with a balloon catheter is the delivery of a therapeutic agent in combination with percutaneous transluminal coronary angioplasty (PTCA), a technique used to dilate stenotic portions of blood vessels. During PTCA, a catheter balloon is positioned at a blocked lumen or target site, the balloon is inflated causing dilation of the lumen. The balloon is deflated and the catheter is then removed from the target site and the patient's lumen thereby allowing blood to freely flow through the unrestricted lumen.
Although PTCA and related procedures aid in alleviating intraluminal constrictions, such constrictions or blockages may reoccur in many cases. The cause of these recurring obstructions, termed restenosis, may be due to the body responding to the surgical procedure. Restenosis of the artery commonly develops over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. Proliferation and migration of smooth muscle cells (SMC) from the media layer of the lumen to the intima cause an excessive production of extra cellular matrices (ECM), which is believed to be one of the leading contributors to the development of restenosis. The extensive thickening of tissues narrows the lumen of the blood vessel, constricting or blocking the blood flow through the vessel. Therapeutic agents selected to limit or prevent restenosis may be locally delivered with PTCA from a catheter and/or by placement of a stent configured to release the therapeutic agent after the PTCA procedure. Catheter balloons may be used in combination with stents, synthetic vascular grafts, or drug therapies, during the PTCA procedure to reduce or eliminate the incidence of restenosis. A number of catheter devices have been developed to administer a therapeutic agent locally to tissue while dilating a body vessel, such as during delivery of a therapeutic agent to a dilated portion of a coronary artery in a PTCA procedure. For instance, a therapeutic agent may be administered directly to the target site through small holes or apertures in the wall of a catheter balloon.
Regardless of the type of balloon catheter, balloon catheters when navigating through the vasculature can experience axial compression along the shaft, thereby making them more difficult to be pushed by the clinician. Furthermore, balloons of the balloon catheters can burst, thereby leaving a distal portion of the balloon in an expanded state. As a result, retraction of the balloon catheter within an introducer sheath becomes challenging. Moreover, if the retraction force applied to the shaft to withdraw the distal portion of the balloon within the introducer sheath is high relative to the tensile strength of the shaft, the shaft is susceptible to breaking or snapping. Any shaft portion that breaks away can be potentially harmful to the patient.
Described herein is a balloon catheter with a rod embedded within a catheter shaft. The catheter shaft can have a polymer filled solid body with an inflation lumen and a guidewire lumen extending at least partially therethrough. The guidewire lumen may extend distally beyond the inflation lumen. A balloon member can be attached to a distal end of the shaft. The balloon member may extend from proximate the distal end of the inflation lumen to proximate the distal end of the guidewire lumen, and can have a balloon interior in communication with the inflation lumen. The embedded rod is extended through at least a portion of the polymer filled solid body along the inflation lumen and the guidewire lumen. The rod is preferably in non-translatable contact with the shaft body, and has a higher melt temperature than the polymer that fills the shaft body. The rod can be disposed within the balloon region of the shaft in order to increase the tensile strength of that region. The rod may be further extended to the proximal region of the shaft for pushability of the shaft during translation through the vasculature. To increase pushability and tractability of the balloon catheter, the rod may include a first length with a first diameter and a second length with a second diameter less than the first diameter, with a tapered region interposed between the first and second lengths.
In another example of the balloon catheter assembly, a catheter shaft can include an outer sleeve extending from a proximal end to a distal end. A first tubular member that defines an inflation lumen and a second tubular member that defines a guidewire lumen can be situated adjacent to one another within the outer sleeve. A thermoformable polymer can be disposed within the outer sleeve and about the first and second tubular members. The thermoformable polymer may fill the voids between the outer sleeve and the first and second tubular members. The catheter shaft can have a distal region and a remaining proximal region, where along the distal region, the second tubular member is extended beyond the first tubular region. The distal region has a tensile strength less than the remaining proximal region. A balloon member can be coupled to the distal region of the catheter shaft, and structured and arranged to permit a balloon interior to be in communication with the inflation lumen. To increase the tensile strength of the distal region of the catheter shaft, a rod can be situated at least partially within the distal region of the catheter shaft along the balloon interior. The rod can be embedded within and in non-translatable contact with the thermoformable polymer and adjacent to the second tubular member within a length of the outer sleeve.
In another embodiment, a method of manufacturing a balloon catheter assembly is also provided. A first tubular member, a second tubular member, and a rod can be aligned substantially parallel and adjacent with respect to each other. Each tubular member may be formed from a fluorinated hydrocarbon tubular liner. The first and second tubular members, the rod, and a thermoformable polymer can be disposed within an outer sleeve comprising a cross-linked heat-shrinkable polymer to form a catheter assembly. The thermoformable polymer may be in contact with the first and second tubular members and the rod, and preferably has a lower melt temperature than the first and second tubular members and the rod. Heat can be applied to the catheter assembly sufficient to melt the thermoformable polymer, and sufficient to shrink the outer sleeve, so that the first and second tubular members and the rod are joined in a fixed orientation to one another within the outer sleeve to define a catheter shaft. An expandable material can be attached to a distal region of the catheter shaft to form a balloon in fluid communication with a distal end of the first tubular member. A distal end of the second tubular member can extend distally beyond the first tubular member.
The present disclosure relates to a balloon catheter assembly for delivering a therapeutic agent to a body vessel, as well as methods of manufacturing the same and methods of treatment using the balloon catheter assembly. For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiments illustrated in the drawings, and specific language will be used to describe the same. It should nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated device, and such further applications of the principles of the invention as illustrated therein being contemplated as would normally occur to one skilled in the art to which the invention relates.
As used herein, the terms “proximal” and “distal” describe longitudinal directions in opposing axial ends of the balloon catheter assembly, and components thereof. The term “proximal” is used in its conventional sense to refer to the end of the device (or component) that is closest to the operator during use. The term “distal” is used in its conventional sense to refer to the end of the device (or component) that is initially inserted into the patient, or that is closest to the patient.
As used herein, the term “therapeutic agent” refers to any medically beneficial compound that may be delivered by a balloon catheter assembly in a fluid form. Preferably, the therapeutic agent is an agent effective to treat or prevent restenosis, such as an antisense agent, a microtubule stabilizing agent or an inhibitor of the mammalian target of rapamycin (mTOR). Preferred antisense compounds include the NeuGene Antisense compounds sold as Resten-NG and Resten-MP by AVI Biopharma, as well as rapamycin, paclitaxel and various analogs or derivatives thereof. Other preferred therapeutic agents are described in U.S. Pat. No. 7,094,765, incorporated herein by reference. Most preferably, the therapeutic agents include an antisense molecule having a morpholino antisense compound with uncharged phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA.
As used herein and unless otherwise indicated, the term “thermoformable” refers in general to a material that may be reshaped under conditions of temperature and/or pressure. Preferably, a thermoformable polymer may be softened or melted under processing conditions to adhere to adjacent structural components. For example, a catheter shaft assembly may include a thermoformable polymer contacting one or more tubular liners and/or a stiffening member. Upon heat and/or pressurized processing of the catheter shaft assembly, the thermoformable polymer may melt or soften, adhering the tubular liners and/or stiffening member to one another. Preferably, the thermoformable polymer has a flowability above a desired processing temperature, but forms a solid having desired resilience and strength properties at a temperature of intended use (e.g., 37° C. (98.6° F.). The catheter shaft may include a thermoformable polymer that adheres to and fills the voids between structural components therein, such as fluorinated hydrocarbon tubular members and/or a stainless steel stiffening member.
In a first embodiment, a balloon catheter assembly for delivering a therapeutic agent is provided as shown in
The manifold 20 is operatively joined to a catheter shaft 30 in a proximal region 500. The manifold 20 may include a lateral injection port 24 and an inflation port 22. The catheter shaft 30 may also include one or more conventional fittings and/or adapters between the manifold 20 and the proximal end of the catheter shaft 30. The balloon catheter assembly 10 is a “short wire” system having a wire guide port 32 within an intermediate region 400 of the catheter shaft 30, providing access to a wire guide lumen extending through the catheter shaft 30 from the wire guide port 32 to the distal end 4 of the catheter shaft 30. Alternatively, the balloon catheter assembly 10 may be an “over the wire” system with the wire guide port 32 positioned proximate the proximal end 2 of the catheter shaft 30 or as part of the manifold 20. That is, the manifold 20 may include the wire guide port 32 in addition to the inflation port 22 and the injection port 24. The distal region 300 of the balloon catheter assembly 10 includes a perforated outer balloon 42 radially disposed around an inner inflation balloon 44. The inner balloon 44 is preferably non-porous and in fluid communication with the inflation port 22 through the body of the catheter shaft 30. The outer balloon 42 is in fluid communication with the injection port 24 through the catheter shaft 30 and separated from both the inner balloon 44 and the inflation port 22. An annular lumen for receiving a therapeutic agent from the injection port 24 may be formed between the inner balloon 44 and the outer balloon 42. Both the inner balloon 44 and the outer balloon 42 may be sealed to the distal end 4 of the catheter shaft 30, within the distal portion 300 of the catheter shaft 30 housing the distal portion of the wire guide lumen. The balloon catheter assembly 10 may be translated over a wire guide 50 shown extending from the wire guide port 32, through the catheter shaft 30 and extending from the distal end 4 of the catheter shaft 30. The balloon catheter assembly 10 is typically provided separately from the wire guide 50, an introducer sheath (not shown) or other devices typically used to insert the balloon catheter assembly 10 within a body vessel.
In operation, the balloon catheter assembly 10 may be introduced to a body vessel by conventional medical procedures, such as the Seldinger technique, and subsequently translated through the body vessel over the wire guide 50 to position the distal region 300 at a point of treatment therein. The inner balloon 44 may be inflated to a desired diameter by injecting a suitable inflation fluid, such as a pressurized air, gas or liquid, through the inflation port 22 in the manifold 20. For example, the inner balloon 44 may be inflated to expand a stenosis in a body vessel such as a coronary artery. Preferably, the inner balloon 44 is inflated until the outer balloon 42 contacts a portion of a body vessel wall at a point of treatment. A fluid containing a therapeutic agent and/or a diagnostic agent (e.g., x-ray contrast media) may be injected through the injection port 24, transported within the catheter shaft 30, and introduced to the annular lumen between the outer balloon 42 and the inner balloon 44. The therapeutic agent fluid may be pressurized to deliver the therapeutic agent to the wall of a body vessel through openings in the outer balloon 42 before, during or after inflation of the inner balloon 44.
In a first aspect of the first embodiment, the catheter shaft 30 is formed from a thermoformable material enclosing one or more tubular members. The tubular members may be formed from a material having a higher melting temperature than the thermoformable material, and may be secured within the catheter shaft by melting or softening the thermoformable material around the outside of the tubular members, without blocking the lumen extending through each tubular member. Preferably, the tubular members are formed from a fluorinated hydrocarbon, such as PTFE or FEP, or a polyimide. The thermoformable material is preferably a polymer, and may include a PEBA polymer or other lower-melting point polymer with a desired level of rigidity and flexibility for forming the catheter shaft 30. The catheter shaft 30 may include tubular members (e.g., 202, 212) having a substantially uniform inner diameter. The wall of the tubular members preferably has a thickness adequate to prevent bursting of the tubular member during inflation and/or delivery of a therapeutic agent fluid. The tubular members are most preferably formed from a fluorinated hydrocarbon, such as poly(tetrafluoroethylene) (PTFE).
In a second aspect of the first embodiment, a proximal portion of the catheter shaft 30 may include a stiffening member, for example stiffening member 210, to improve the pushability and/or tractability of the balloon catheter assembly 10.
The stiffening member 210 can be any size, and may have a uniform diameter throughout such as in the range of about 0.43 mm (0.017 inches) or larger to about 0.05 mm (0.002 inches) or smaller. The stiffening member 210 may be a tapered mandrel having a cross sectional area that decreases in the distal direction along the catheter shaft 30. For example, a stiffening member may be formed from a 0.38 mm (0.015-inch) diameter proximal end tapered to a distal end with a diameter of about 0.05 mm (0.002-inch) or smaller. Other stiffening members and/or tapering configuration can be found in
Referring to
The balloon catheter assembly 10 may be configured with a desirably small outer diameter, a sufficiently flexibility to pass through a tight curvature or tortuous passageway, and a pushability and tractability sufficient to be navigated through such tightly curved and/or tortuous pathways in the same manner as a wire guide. A preferred outer diameter will be different for different applications, but the outer diameter a catheter embodiment configured for use in peripheral blood vessels may be in the range of about 1.0-1.4 mm (0.040-0.055 inches), and that the outer diameter may differ along the length of the catheter embodiment. The catheter shaft 30 may optionally be configured as a rapid exchange catheter, as shown in
The catheter shaft 30 may optionally further include a coating on the outer sleeve 31. A preferred coating may provide a desirable lubricity profile that exhibits low friction during introduction of the device through, for example, a blood vessel. A preferred coating may also provide a fluid-tight seal configured to prevent leakage of pressurized inflation fluid (for example, at pressures in a normal operating range up to about 0.8-1.4 MPa (8-14 atm), and preferably configured to prevent leakage at pressures exceeding normal ranges, for example, up to or exceeding about 2.7 MPa (27 atm)). The coating may be a thermoplastic polymer such as, for example, a polyester or polyether block amide (e.g., PEBAX®).
In one example, to form the catheter shaft 30, the first tubular member 202 and the second tubular member 212 may be placed within each of the two lumens of a dual lumen thermoplastic sleeve formed from a thermoformable material 36 and having a “figure 8” transverse cross section defining two lumens with a wall thickness of at least about 0.064 mm (0.0025-inches) between the two lumens. Optionally, each of the tubular members 202, 212 may be supported within the thermoplastic sleeve lumens on separate temporary mandrels while being inserted into the thermoplastic sleeve. The thermoplastic sleeve lumens may have any suitable inner diameters to receive the tubular members 202, 212, such as between about 0.38 mm (0.015-inches) and 0.51 mm (0.020-inches). Optionally, the thermoplastic sleeve may include a first lumen and a second lumen with substantially identical inner diameters. Alternatively, the thermoplastic sleeve may include a first lumen with an inner diameter of about 0.38 mm (0.015-inches) and a second lumen with an inner diameter of about 0.46-0.64 mm (0.018-0.025-inches). Both lumens within the thermoplastic sleeve are preferably substantially parallel to one another and extend along the entire length of the thermoplastic sleeve. The dual-lumen thermoplastic sleeve may be constructed of a thermoformable material 36 such as, for example, a polyolefin, polyester or polyether block amide (PEBA), or other appropriate polymeric material that may be heated to flow around and join together the tubular members 202, 212 within the lumens of the thermoplastic sleeve to the stiffening member 210 and a third tubular member 222 positioned adjacent the thermoplastic sleeve (i.e., external to the lumens of the thermoplastic sleeve but within the outer sleeve 31).
As indicated above, to further improve pushability and tractability of the balloon catheter assembly 10, the stiffening member 210 is preferably integrally joined to the tubular members 202, 212 along side the thermoplastic sleeve, with the tapered distal end of the stiffening member distal (e.g., 5 cm mm) to the wire guide port 32. Preferably, the stiffening member 210 is not inserted through a lumen within the thermoplastic sleeve, but rather, is integrally formed within the catheter shaft after heat processing of the thermoplastic sleeve to permit a thermoformable material 36 flow around the stiffening member 210 and the tubular members 202, 212, 222 during processing to form a single catheter shaft after heat and/or pressure processing. The stiffening member 210 may be positioned outside the thermoplastic “figure 8” sleeve but inside the outer sleeve 31. The outer sleeve 31 may be formed of any suitable heat-shrinkable material that is capable of forming a secure bond with the dual-lumen thermoplastic sleeve and/or one or more of the tubular members 202, 212, 222.
The catheter shaft 30 may be formed by enclosing the dual-lumen thermoplastic sleeve having the “figure-8” cross-section defining a first lumen and a second lumen and the stiffening member 210 within the outer heat-shrinkable sleeve. A heat shrinkable outer sleeve 31 may be placed around the thermoplastic sleeve, the tubular members 202, 212, 222 and the stiffening member 210. The outer sleeve 31 typically has a higher melting point than that of the thermoformable material 36 of the thermoplastic sleeve. When the thermoplastic sleeve comprises a nylon or PEBA, a preferred outer sleeve 31 material comprises a copolymer, and more preferably, a block copolymer such as a cross-linked polyether block amide (PEBA). Block copolymers comprise alternating segments formed of a harder, or more crystalline material, and a softer, or more amorphous, material. When the copolymer is PEBA, the harder material comprises a polyamide, such as nylon 12, and the amorphous segments comprise polyether. The hard and the amorphous segments are linked together by urethane groups in known fashion. By varying the ratio of the polyamide to polyether blocks, PEBA compositions of varying properties, such as melting point, dimensional stability, hardness, etc., may be created. Commercially available grades of PEBA typically have a Shore hardness between about 72 D and 75 A. Higher polyamide to polyether ratios will result in a higher Shore hardness (stiffer material), and lower polyamide to polyether ratios result in a lower Shore hardness (softer material).
Typically, the outer sleeve 31 comprises a thermoplastic material that is subjected to at least partial cross-linking. The thermoformable material 36 is preferably free of crosslinking or has a reduced degree of cross linking compared to the outer sleeve 31. When a polymeric material is cross-linked, chemical links are established between the molecular chains of the polymer, thereby resulting in a change of properties in the cross-linked material when compared to the non-cross-linked material. In general, when a material is cross-linked, the properties of the cross-linked material cause it to behave more in the nature of a thermoset material. Thus, the resulting material may have higher dimensional stability (hoop strength), higher tensile strength, higher stiffness and density, higher melting temperature, improved heat memory, improved chemical resistance, and improved physical strength, among other properties, when compared to the non-cross-linked thermoplastic. Similarly, some properties, such as elongation and the ability to flex, are generally lower in the cross-linked material when compared to the non-cross-linked material. Thus, for example, when the cross-linked material is a block copolymer such as PEBA, the properties of the resulting cross-linked material will generally differ from those of the original block copolymer in the manner described above. It is often desirable to control the amount, or degree, of cross-linking of a particular block copolymer in order to optimize the desired properties of the cross-linked polymer. In some instances, a trade-off must be made to arrive at a copolymer that is sufficiently cross-linked to be effective for its intended purpose, but not so highly cross-linked as to effectively negate the beneficial results of the cross-linking.
The outer sleeve 31 preferably includes a cross-linked PEBA polymer, while the thermoformable material 36 is preferably a non-cross-linked PEBA polymer. Cross-linking procedures are well known in the arts. Typically, cross-linking is initiated by chemical means, or by irradiation. With chemical initiation, an initiating compound, such as a peroxide, is mixed into the matrix of the polymer. With irradiation, a material is exposed to high-energy radiation to initiate the formation of the molecular bonding. Both of these methods have been found to effectively promote molecular bonding within the material. In modern practice, irradiation is probably the more common mode for initiating the cross-linking reaction. Examples of procedures involving the cross-linking of polymeric compositions for use in medical applications are discussed, e.g., in U.S. Pat. No. 6,663,646 and U.S. Pat. No. 6,596,818, the disclosures of which are incorporated by reference herein. The outer may include other cross-linkable polymers, with or without PEBA. A copolymer may be formed of alternating hard blocks and amorphous blocks. Similarly, the copolymer may be selected such that following cross-linking, the copolymer has a sufficient number of non-cross-linked active sites (analogous to the amide sites on the PEBA copolymer) that are capable of forming a secure bond with the adjoining inner layer of the sheath. A non-limiting list of other polymeric compositions that may be utilized as an outer heat shrink layer under appropriate conditions includes polyolefins, PET and FEP.
The assembly of the tubular members, the dual-lumen thermoplastic sleeve and the outer heat-shrinkable sleeve can be joined together by heating a catheter assembly to a temperature suitable to melt or soften the thermoformable material 36 and shrink the outer sleeve 31, but below a temperature effective to melt or soften the tubular members 202, 212. Upon exposure to a controlled amount of heat, the thermoformable material 36 may melt and flow between the interstices within the outer sleeve 31, and is fused to the outer surfaces of the tubular members 202, 212, 222 and the stiffening member 210. The outer sleeve 31 may compress the thermoformable material 36, the tubular members 202, 212, 222 and the stiffening member 210 together to form the catheter shaft 30 in a conventional manner when heat shrink techniques are used to form the catheter shaft 30. Those skilled in the art will appreciate that the outer sleeve 31 and a polymeric thermoformable material 36 may be formed from a variety of medical grade materials suitable for such purposes, so long as the layers are capable of being fused or otherwise bonded or securely attached to each other upon the application of heat, as described. The temperature may vary widely, depending on material. Polyolefin has a low shrink temperature of about 290° F. (143° C.), however it can withstand temperatures up to about 450° F. (232° C.). PET shrinks at 302° F. (150° C.) but melts at 374° F. (190° C.). PEBA shrinks at 340° F. (171° C.) and will not degrade at temperatures under about 500° F. (260° C.). FEP shrinks at 375° F. (190° C.), but does not degrade until temperatures exceed 600° F. (315° C.). For example, the catheter assembly may be heated to a temperature of about 400-550° F. (204-288° C.) and preferably about 500° F. (260° C.), to join the dual-lumen sleeve comprising the thermoformable material 36, the two tubular members 202, 212 and the stiffening member 210 within the heat-shrinkable outer sleeve 31 to form the balloon catheter assembly 10. If present, the temporary mandrels may be removed from the lumens of the tubular members 202, 212 after heat processing to join the assembly together. Optionally, the assembly may be heated while enclosed in a suitable bonding sleeve, such as an FEP heat shrink material, to provide heat-transmitting contact to the outer sleeve 31 during processing. The bonding sleeve may later be removed along with any temporary mandrels within the tubular members 202, 212.
The balloon catheter assembly 10 is preferably configured as a “short-wire” configuration, where the wire guide lumen 226 may not extend the entire length of the catheter shaft 30. In this type of catheter, the wire guide lumen may extend only from the distal end 4 of the balloon catheter assembly 10 to a point intermediate the distal end 4 and manifold 20 at the proximal end of the catheter shaft 30. The shorter guide wire lumen 226 facilitates the exchange a first balloon catheter assembly 10 for other medical devices, such as a second catheter (e.g., to “exchange out” a balloon catheter, and then “exchange in” a stent-deployment catheter). Referring to
Referring to
Referring to
Preferably, the radially outer surface of one or more of the tubular members 202, 212, 222 is roughened in any conventional manner, such as by chemical etching, to form a rough outer surface to facilitate bonding with a dual-lumen thermoplastic sleeve and/or a heat-shrinkable (thermoset) outer sleeve 31 as described above.
In one example, the third tubular member 222 may be incorporated into the balloon catheter assembly 10 by placing the third tubular member 222 adjacent to and along side the dual-lumen thermoplastic “figure 8” sleeve formed from a thermoformable material 36 enclosing the first tubular member 202 and the second tubular 212, described above. The third tubular member 222 may be placed with its proximal end 222a overlapping with the distal end of the tapered stiffening member 210 within the outer heat-shrinkable sleeve. Upon heating the assembly, the thermoplastic sleeve and the outer heat shrinkable sleeve join the first tubular member 202, the second tubular member 212, the third tubular member 222 and the stiffening member 210 together to form the catheter shaft 30. The wire guide port 32 may be formed by cutting away an aperture in the outer sleeve 31 to access the proximal end 222a of the wire guide lumen 226 within the third tubular member 222. The distal end 222b of the wire guide lumen 226 may form the distal end 4 of the catheter shaft 30.
The inner balloon 44 and the outer balloon 42 may be formed from a semi-compliant expandable material. Preferably, the inner balloon 44 and the outer balloon 42 are formed from the materials having a similar Young's modulus and expandability. For example, the balloons may be formed from a polyamide (e.g., nylon 12) material, a polyamide block copolymer (e.g., PEBA) and blends thereof (e.g., nylon 12/PEBA and PEBA/PEBA blends). Alternative materials include polyolefins, polyolefin copolymers and blends thereof; polyesters (e.g., poly(ethylene terephthalate), PET); polyurethane copolymers with MDI, HMDI or TDI hard segment and aliphatic polyester, polyether or polycarbonate soft segment (e.g., Pellethane, Estane or Bionate); and polyester copolymers with 4GT (PBT) hard segment and aliphatic polyester or polyether soft segments (e.g., Hytrel, Pelprene or Arnitel).
The proximal seal and distal seal of each balloon (242a, 242b, 244a, 244b) may be formed in any suitable manner. Typically, the proximal and distal inner surfaces of the balloons 42, 44 are sealably attached to the catheter shaft 30 or a tubular member, as described above. Means of sealing the balloons 42, 44 include, for example, heat sealing, using an adhesive to form the seal, forced convection heating, radio frequency heating, ultrasonic welding, and laser bonding. Shrink tubing may be used as a manufacturing aid to compress and fuse the balloon 42, 44 to the catheter shaft 30 or a tubular member 202, 212, 222. The shrink tubing may be removed and disposed of after the balloon 42, 44 is sealed, or may remain on as part of the connected structure. If the catheter shaft 30 has an outer coating, the balloon 42, 44 may be bonded to the coating or directly to the catheter shaft 30.
When configured for use in a peripheral blood vessel, the inflated diameter of the outer balloon 42 may be about 1.5 mm (0.059-inches) to about 8 mm (0.3-inches), while a catheter intended for coronary vascular applications preferably has an expandable portion 14 with an inflated diameter range of from about 1.5 mm (0.059-inches) to about 4 mm (0.2 inches). When configured for use in bile ducts, the expanded diameter of the outer balloon 42 may be about 5-15 mm (0.2-0.59-inches) with a length of approximately 15-60 mm (0.59-2.4 inches), and the outer diameter of the catheter shaft 30 may be up to about 3.5 mm (0.14-inches). The catheter shaft may be about 3-12 French between proximal to the balloons (i.e., an outer diameter of about 1 mm-4 mm (0.04-0.16-inches)), and preferably about 4-8 French.
Optionally, the balloon catheter assembly 10 may include radiopaque material to provide a means for locating the balloon catheter assembly 10 within a body vessel. For example, the third tubular member 222 may include one or more marker bands 252 annularly disposed around the outside of the third tubular member 222 within the inner balloon 44. If desired, radiopaque bands 252 may be added to the third tubular member 222. Radiopaque marker bands 252 may be used by a clinician to fluoroscopically view and locate the distal portion 300 of the balloon catheter assembly 10 at a treatment site within a body vessel. Various configurations of radiopaque marker bands 252 may be used. For example, radiopaque marker band 252 may be located on a distal end 4 and/or on the third tubular member 222 within the inner balloon 44. As shown, the radiopaque marker bands 252 may be stripes. Such radiopaque markers may be constructed by encapsulating a radiopaque material, such as a metallic ring, within the material of catheter shaft. Alternatively, a portion of the catheter shaft may be made radiopaque for example by constructing the portion from a radiopaque polymer. For example, a polymer may be mixed with a radiopaque filler such as barium sulfate, bismuth trioxide, bismuth subcarbonate or tungsten. The radiopaque material can comprise any suitable opacifying agent, further including bismuth, tantalum, or other suitable agents known in the art. The concentration of the agent in the coating may be selected to be adequately visible under fluoroscopy.
The outer balloon 42 may include a means for releasing a therapeutic agent from the balloon fluid delivery lumen 242. For example, the outer balloon 42 may define a plurality of openings in communication with the balloon fluid delivery lumen 242.
In another aspect of the first embodiment, fluid delivery catheters having a higher burst pressure for a given outer diameter are provided. In generally, fluid delivery catheters are desirably made small and thin. Accordingly, their structural strength may be limited by the thickness and type of material forming the catheter's walls. The amount of pressure and flow rate that the catheter can support without damage may also be limited. If the maximum pressure the catheter can withstand (the burst pressure) or the maximum flow rate is exceeded, the catheter may be damaged or may completely fail possibly spilling fluids from the catheter into the body. During high pressure injections, escaping fluid may also damage the surrounding tissues. The catheter shaft configurations described provide increased burst pressure without requiring an increase in the diameter of the fluid delivery lumen or the outer diameter of the catheter shaft by including one or more tubular members (e.g., 202, 212) lining lumens extending through the catheter shaft. This permits lower fluid delivery pressures for a given burst pressure, compared to catheter shaft configurations without the tubular members. Exemplary catheter shaft configurations may have an outer diameter of about 1.1 mm (0.042-inches) and a fluid delivery lumen having an inner diameter of about 0.36 mm (0.014-inches), and a burst pressure of about 2.7-3.5 MPa (27-35 atmospheres) or more. The individual tubular members may be perfluorocarbon liners with a burst pressure of about 1.5 MPa (15 atmospheres) at about 0.25 mm (0.010-inches) to 0.33 mm (0.013-inches) thickness. A fluid delivery catheter for medical procedures may include a shaft portion having a distal end insertable into a body lumen, the shaft portion including a wall defining a fluid delivery lumen extending therewithin and a first tubular member coupled to the wall to increase a burst pressure of the shaft portion, wherein the first liner cooperates with a material of the wall to define a flexible region of the shaft portion allowing the shaft portion to be atraumatically inserted into the body lumen.
In one particular aspect, an intraluminal drug delivery catheter assembly may include a means for expandably contacting the balloon with the wall of a body vessel (e.g., one or more balloons) and/or a means for delivering a therapeutic agent through the catheter shaft (e.g., a plurality of apertures in the balloon). The catheter shaft may extend from a proximal end to a distal end and define an inflation lumen spaced from a fluid delivery lumen. The catheter shaft may be formed in part by a thermoformable polymer and include a stiffening member within a portion of the catheter shaft in non-translatable contact with the thermoformable polymer. The catheter assembly may include a balloon comprising a plurality of apertures mounted around at least a portion of the distal end of the catheter shaft, with at least a portion of the plurality of apertures having a total cross sectional area that increases in a distal direction along the second balloon.
In another particular aspect, the catheter assembly may include an outer sleeve enclosing a thermoformable material and one or more fluid delivery lumens lined with a liner material such that the burst pressure of the catheter assembly is greater than the burst pressure of the thermoformable material, the outer sleeve, and the liner material independent of one another. Methods of increasing the burst pressure of a catheter shaft may include providing a fluorinated carbon liner and an outer sleeve, as described herein, to a conventional catheter shaft formed from a thermoformable material.
In another embodiment, methods of delivering a therapeutic agent to a body vessel are provided. Preferably, the methods include the step of inserting into a body vessel a therapeutic agent delivery balloon catheter assembly over a wire guide. The balloon catheter assembly may include any balloon catheter assembly disclosed herein. For example, the balloon catheter assembly may include: (1) a catheter shaft extending from a proximal end to a distal end and including one or more tubular members that may define an inflation lumen adjacently spaced from a fluid delivery lumen and/or a wire guide lumen, the catheter shaft formed in part by a thermoformable polymer; (2) a deflated first balloon mounted on the distal end of the catheter shaft in communication with the inflation lumen; (3) a deflated second balloon mounted around at least a portion of the first balloon on the distal end of the catheter shaft in communication with the fluid delivery lumen, defining an annular balloon fluid delivery lumen between the first balloon and the second balloon. The second balloon preferably includes a plurality of apertures in the second balloon in communication with the balloon fluid delivery lumen, the plurality of apertures having a total cross sectional area that increases in a distal direction along the second balloon. The catheter shaft preferably includes a stiffening member within a portion of the catheter shaft in non-translatable contact with the thermoformable polymer. The balloon catheter assembly may be translated through the body vessel over a wire guide slidably extending through the wire guide lumen to a point of treatment. The first balloon may be inflated at the point of treatment to place the second balloon in contact with the wall of the body vessel.
A therapeutic agent may be delivered through the fluid delivery lumen at a pressure effective to deliver the therapeutic agent to the wall of the body vessel through the plurality of apertures in the second balloon. The therapeutic agent may be delivered by direct local administration to the vessel site or injury through the plurality of apertures in the second balloon. The antisense compound may have: (i) morpholino subunits linked together by phosphorodiamidate linkages, 2 atoms long, joining the morpholino nitrogen of one subunit to the 5′ exocyclic carbon of an adjacent subunit; and (ii) a sequence of bases attached to the subunits and containing a therapeutically beneficial antisense nucleotide sequence. While the compound need not necessarily 100% complementary to the target sequence, it is preferably effective to stably and specifically bind to the target sequence such that expression of the target sequence is modulated. The appropriate length of the oligomer to allow stable, effective binding combined with good specificity is about 8 to 40 nucleotide base units, and preferably about 12-25 base units. Mismatches, if present, are less destabilizing toward the end regions of the hybrid duplex than in the middle. Oligomer bases that allow degenerate base pairing with target bases are also contemplated, assuming base-pair specificity with the target is maintained. The compound preferably contains internal 3-base triplet complementary to the AUG site, and bases complementary to one or more bases 5′ and 3′ to the start site. One preferred compound sequence is the 20mer having the base sequence: 5′-ACG TTG AGG GGC ATC GTC GC-3′, where the CAT triplet in the sequences binds to the AUG start site, the 6 bases 3′ to the CAT sequence extend in the upstream (5′) direction on the target, and the 11 bases 5′ to the CAT sequence extend downstream on the target. This compound has enhanced solubility by virtue of having no self-annealing regions. Preferably, the therapeutic agent is a morpholino antisense compound having (i) from 8 to 40 nucleotides, including a targeting base sequence that is complementary to a region that spans the translational start codon of a c-myc mRNA; and (ii) uncharged, phosphorus-containing intersubunit linkages, in an amount effective to reduce the risk or severity of restenosis in the patient. These therapeutic agents are described in U.S. Pat. No. 7,094,765 and published US patent application US 2006/0269587 A1, which are incorporated herein by reference in their entirety. While the therapeutic agent is described with respect to certain preferred antisense compounds, any suitable therapeutic agent in fluid form (i.e., a gas and/or a liquid) or in a fluid carrier may be delivered from the balloon catheter assembly.
The balloon catheter assembly 10 shown in the figures herein is one preferred embodiment of the invention that includes a dual balloon assembly at the distal end of the catheter shaft 30. Other embodiments preferably include a catheter shaft extending from a proximal end to a distal end and defining an inflation lumen spaced from a fluid delivery lumen, the catheter shaft formed in part by a thermoformable polymer. The catheter shaft may include one or more balloons comprising a plurality of apertures mounted around at least a portion of the distal end of the catheter shaft, a means for delivering a therapeutic agent through the catheter shaft through the plurality of apertures in the balloon and/or a means for expandably contacting the balloon containing the apertures with the wall of a body vessel. In the embodiment described with respect to the figures above, the means for delivering a therapeutic agent is exemplified as a fluid delivery lumen defined by a second tubular member 212. Alternative structures may be substituted as a means for delivering the therapeutic agent through the catheter shaft, such as a lumen formed within the thermoformable material 36 without the tubular member 212, or a lumen formed in a second catheter shaft or a second tube adhered to the outside of the catheter shaft 30. Alternative structures may also be substituted as a means for expandably contacting the balloon with the wall of a body vessel, which is exemplified in the figures as including an inner balloon 44. For example, a single balloon containing apertures or a microporous membrane may be used as the perforated balloon and the means for contacting the balloon. Alternatively, an expandable frame or other mechanical means may be used to contact a perforated balloon with the body vessel. Other single balloon embodiments are described below.
An exemplary method of making the balloon catheter assembly 10 is described with reference to
As shown in
Referring to
Referring to
Catheter shaft burst pressure was measured. One end of the shaft to be measured was closed off and the interior of the shaft was pressurized with a measurable source, until a discontinuity or fault (such as a hole) developed in the shaft. The pressure was measured in atmospheres (atm) using a burst tester such as a PT-3070 Burst Tester (Laguna Niguel, Calif.). Each component was pressurized in 1 atm (0.1 MPa) increments using a pressurization rate of 0.40 ml/s starting at 1 atm (0.1 MPa) and held at each pressure for three seconds. A failure was defined as a drop in pressure of 1.50 atm (0.15 MPa) or greater during the three second hold. Four separate burst pressures were measured for each of three component portions of the catheters: a perfluorocarbon liner (202, 212, 222), a thermoformable “figure 8”-shaped tubing having an inner diameter of 0.0215-inches (0.546 mm) with a wall of 0.0025-inches (0.064 mm) (36), and a PEBAX heat-shrink outer liner (31). The burst data for each sample is shown in Table 1. The liners burst at about 19-20 atmospheres (1.9-2 MPa), at which pressure fluid could no longer be contained within the liners. The thermoformable tubing and outer liners burst at lower pressures.
Next, the burst pressure of a catheter assembly (10) as shown in
The balloon catheter assemblies (10) were constructed according to the preferred embodiment of Example 1. The burst data for each sample is shown in Table 2.
Notably, the burst pressures of the catheter assemblies (10) were each at least about 30 atmosphere (3 MPa) (27-35 atmospheres (2.7-3.5 MPa)), while the individual liners tested above burst at a lower pressure of about 20 atmospheres (2 MPa). Therefore, while fluid above 20 atmospheres (2 MPa) could not be contained by any one of the liners, thermoformable material or outer sleeve individually, pressures of at least about 30 atmospheres (3 MPa) could be conducted along the catheter shaft assemblies of Example 1.
Various features of the stiffening member of the present disclosure will now be described. It is contemplated that any of the embodiments of the stiffening member can be embedded into any catheter shaft, and in particular any balloon catheter shaft, such as, e.g., multiple balloon configurations, as well as single balloon configurations. The balloons may be configured to deliver a therapeutic agent and/or dilate narrowed portions of the body vessel. The balloon catheter assembly incorporating the stiffening member can be an “over the wire” system or a “short wire” system.
A stiffening member 930, having at least some of the features as the stiffening member 210 or 610 and which can be assembled to form the shaft as described above, can be positioned to cross between the intermediate region 912 and the distal region 914 and reside within the distal region 914, as shown in
As mentioned previously, the assembly of the balloon catheter assembly 910 can include one or more of the steps described herein, e.g., with reference to
Stiffening member 1010 can advantageously provide a variable stiffness balloon catheter assembly. A first stiffness is provided along proximal length 1012 in order to achieve greater pushability at the proximal length of the catheter shaft. A second stiffness is provided along the distal length 1014 in order to achieve greater tractability through more tortuous anatomy. The stiffening member 1010 may also decrease the sponginess or axial compression often found in balloon catheters by increasing the amount of force transferred from the proximal end and to the distal tip. To this end, longer lengths of the balloon catheter assemblies may be achieved that have sufficient pushability and tractability for a clinician accessing a site farther from conventional insertion points.
As mentioned previously, the assembly of a balloon catheter assembly including stiffening member 1010 can include one or more of the steps described herein, e.g., with reference to
Various combinations of stiffening members are further contemplated. For example, the distal length of the stiffening member 1010 or 210 can be extended farther into the balloon region of the catheter shaft such as described above with respect to
Those of skill in the art will appreciate that other embodiments and variants of the structures and methods described above may be practiced within the scope of the present invention. It is therefore intended that the foregoing detailed description be regarded as illustrative rather than limiting, and that it be understood that it is the following claims, including all equivalents, that are intended to define the spirit and scope of this invention.
The present application is a continuation-in-part of U.S. patent application Ser. No. 12/676,786, filed on Mar. 5, 2010, which is a National Phase Filing of PCT Patent App. No. PCT/US08/75970, filed on Sep. 11, 2008, which claims priority to U.S. provisional application Ser. No. 60/971,802, filed on Sep. 12, 2007, each of which is incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 60971802 | Sep 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12676786 | Nov 2010 | US |
| Child | 13025821 | US |
